Research programme: antibacterials - AlamXAlternative Names: Antibacterials research programme - AlamX; Beta-lactamase inhibitors - AlamX
Latest Information Update: 23 Aug 2006
At a glance
- Originator AlamX LLC
- Mechanism of Action Beta lactamase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 23 Aug 2006 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 18 Aug 2000 Preclinical development for Bacterial infections in USA (Unknown route)